Innovative Cellular Therapeutics Holdings Ltd
10% owner
Sale 10b5-1
- Shares
- 10
- Price
- $13.70
- Value
- $137.00
SEC EDGAR · Forms 3/4/5Updated through Oct 30, 2026•62 filings
LYEL
Lyell Immunopharma, Inc.
No net buying or selling imbalance over the last 3 months
No net buyers or sellers account for the net balance. There is no cluster of three distinct buyers within 30 days. We found no CEO/CFO purchases over 12 months.
How to read this signal
Only open-market P purchases and S sales count toward the signal. Vesting, options, taxes and gifts remain in the source data but do not trigger alerts. Rule 10b5-1 trades are shown as informational.
3-month balance
$0.00
0 buyers · 0 sellers
12-month purchases
$24,999,970
14 distinct insiders
12-month sales
$74,455
2 distinct insiders
Highlighted alerts
4
2 Rule 10b5-1 trades treated as informational
Buying cluster · 30 days
Fewer than three distinct buyers
CEO/CFO purchases · 12 months
No executive purchases found
Get LYEL insider trades by API
The same filtered trades as JSON for your scripts, alerts or AI agent, for 5,500+ US companies — plus sentiment, news, financials and breakout setups. Free · every API · 1,000 requests a month · no card required.
LYEL overview: breakout setup, X sentiment and insiders in one page →
Form 4 raw → Raspberry
The value is in what we do not call a signal.
The SEC XML stores every transaction. Raspberry keeps that evidence, reads the footnotes and separates voluntary open-market activity from vesting, option exercises, gifts, tax withholding, stock purchase and dividend reinvestment plans and pre-programmed 10b5-1 trades.
72
Raw transactions
Everything returned by the filing
6
Voluntary view
P/S trades after deterministic checks
62
Administrative noise
Stored, never alerted
2
10b5-1
Shown as informational
SEC ownership XML facts
- Code
- S
- Shares
- 422
- Price
- $8.63
- Footnotes
- 2
Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $8.54 to $8.63 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Raspberry interpretation
Informational — no alert
Reason: tax_withholding. The filing footnotes identify tax withholding.
Recent transactions
Voluntary purchases and sales; administrative noise stays hidden.
Innovative Cellular Therapeutics Holdings Ltd
10% owner
Sale 10b5-1
- Shares
- 10
- Price
- $13.73
- Value
- $137.30
ARCH Venture Partners IX, LLC
10% owner
PurchaseAlert
- Shares
- 488,090
- Price
- $25.61
- Value
- $12,499,985
ARCH Venture Fund XIII, L.P.
10% owner
PurchaseAlert
- Shares
- 488,090
- Price
- $25.61
- Value
- $12,499,985
Bulis Veronica Sanchez
VP, Corporate Controller
SaleAlert
- Shares
- 936
- Price
- $32.32
- Value
- $30,252
Bulis Veronica Sanchez
VP, Corporate Controller
SaleAlert
- Shares
- 1,136
- Price
- $38.67
- Value
- $43,929
| Date | Insider | Transaction | Shares | Price | Value | Reading |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Sale | 10 | $13.70 | $137.00 | |
| Jul 16, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Sale | 10 | $13.73 | $137.30 | |
| Mar 06, 2026 | ARCH Venture Partners IX, LLC 10% owner | Purchase | 488,090 | $25.61 | $12,499,985 | |
| Mar 06, 2026 | ARCH Venture Fund XIII, L.P. 10% owner | Purchase | 488,090 | $25.61 | $12,499,985 | |
| Dec 30, 2025 | Bulis Veronica Sanchez VP, Corporate Controller | Sale | 936 | $32.32 | $30,252 | |
| Dec 24, 2025 | Bulis Veronica Sanchez VP, Corporate Controller | Sale | 1,136 | $38.67 | $43,929 |
“Alert” means a voluntary, unscheduled transaction according to the filing; it is not an investment recommendation. Official source: SEC EDGAR.